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ABSTRACT
Background
Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action.
Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the
natural history of T2DM, although underlying mechanisms remain obscure.
Methods and Findings
We combined human insulin/glucose clamp physiological studies with genome-wide
expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose
expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals,
its expression was inversely correlated to total body measures of glucose uptake. Forced
expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing
with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake,
confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is
consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450
Scandinavian individuals, we found no evidence for association between common genetic
variation in the TXNIP gene and T2DM.
Conclusions
TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose
uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in
pancreatic b-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective
glucose homeostasis preceding overt T2DM.
The Editors’ Summary of this article follows the references.
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Type 2 diabetes mellitus (T2DM) is a growing worldwide
epidemic that is characterized by defects in insulin secretion,
failure to suppress hepatic glucose output, and impaired
glucose uptake in target tissues, such as skeletal muscle and
fat [1]. Impaired glucose uptake in muscle (both insulin-
dependent and -independent) is believed to be one of the
earliest features in the natural history of T2DM, and insulin
resistance predicts future T2DM [2–4]. Although obesity is the
most important risk factor for insulin resistance in the
prediabetic state [5], other factors such as the toxic effects of
elevated glucose (glucotoxicity) and lipids (lipotoxicity) also
contribute to insulin resistance with progression of the
disease [6]. The mechanisms by which glucose and lipids
induce insulin resistance are not entirely clear but are
thought to involve increased serine phosphorylation and
deactivation of the insulin receptor [7].
In the current study, we combined evidence from human
physiology, genome-wide expression proﬁling, human genet-
ics, and in vitro studies to study novel mechanisms of skeletal
muscle insulin resistance and to identify mediators of glucose
homeostasis that may be causally involved in the development
of T2DM.
Methods
Clinical Participants and Evaluation
Results from three separate clinical studies (studies A, B,
and C) are reported here. Participants in all three studies
underwent an oral glucose (75 g) tolerance test, and glucose
tolerance was diagnosed according to the World Health
Organization criteria [8]. Studies A and B included six
nondiabetic volunteers, while study C included 96 young
(aged 25–32 y) nondiabetic twins. Details of study C were
described previously [9,10]. None of the study participants
were engaged in vigorous exercise on a routine basis, and
they were directed to avoid extreme physical exercise and
alcohol intake for at least 2 d before the studies. The study
participants were asked to fast for 10–12 h before examina-
tion days. Oral and written approval was obtained from each
individual in all of the clinical studies. Clinical and
biochemical characteristics of participants in studies A, B,
and C are provided in Table S1. All clinical studies were
approved by the regional Ethics Committees and were
conducted according to the principles of the Helsinki
Declaration.
Clamp Studies
Studies A and C. The clamp protocol for studies A and C
(Figure S1) involved a 2-h hyperinsulinemic euglycemic clamp
preceded by a 30-min intravenous glucose tolerance test
(IVGTT) to determine ﬁrst-phase insulin secretion as
previously described [10]. A primed continuous infusion of
a 3-[
3H]-glucose tracer was supplied from the time point 160
min and throughout the clamp experiments. The basal
glucose turnover rates (Ra and Rd) were determined during
steady state conditions from 70 to 40 min. After the IVGTT
a primed continuous insulin infusion (40 mU/m
2/min) was
initiated and continued for 2 h. The insulin-stimulated steady
state period was deﬁned as the last 30 min of the 2-h clamp
period. A variable infusion of glucose (180 g/l) enriched with
tritiated glucose (100 lCi/500 ml) maintained euglycemia
during insulin infusion, with monitoring of plasma glucose
concentration every 5–10 min during the basal and clamp
periods using an automated glucose oxidation method
(Glucose Analyzer 2, Beckman Instruments, http://www.
beckmancoulter.com). Indirect calorimetry was performed
during the basal and insulin-stimulated steady state periods
using a computerized ﬂow-through canopy gas analyzer
system (Deltarac, Datex, http://www.us.datex-ohmeda.com).
Study B. The clamp protocol for study B (Figure S1)
involved a 3-h hyperinsulinemic (infusion rate 40 mU/m
2/
min) euglycemic clamp in order to increase the effects of
insulin on gene expression. A variable infusion of glucose
(180 g/l) was used to maintain euglycemia during insulin
infusion with monitoring of plasma glucose concentration
every 5–10 min using an automated glucose oxidation
method (Glucose Analyzer 2, Beckman Instruments). No
IVGTT was performed prior to the insulin infusion.
Furthermore, no glucose tracers or indirect calorimetry was
performed.
Skeletal Muscle Biopsies
From  40 to  30 min (i.e., prior to the IVGTT), a basal
muscle biopsy was taken in studies A and C (Figure S1). In
study B, the basal muscle biopsy was obtained before insulin
stimulation (Figure S1). The second (insulin-stimulated)
muscle biopsy was taken at the time point þ120 min in
studies A and C, whereas in study B it was taken at the time
pointþ180 min. The muscle biopsies were obtained from the
vastus lateralis muscle under local anesthesia in participants
participating in all three studies using a modiﬁed Bergstro ¨m
needle (including suction) before and after the hyperinsuli-
nemic euglycemic clamps. Thus, both biopsies were deter-
mined during carefully standardized basal and insulin-
stimulated euglycemic conditions. Biopsies were immediately
frozen in liquid nitrogen and stored at  80 8C for later
analysis.
Human Biochemical Calculations
Plasma insulin concentrations were analyzed as previously
described [10]. Insulin-stimulated glucose uptake was deﬁned
as the glucose infusion rate during steady state of the clamp.
The glucose uptake and glucose oxidation were expressed per
kilogram of lean body mass as determined by DEXA scan as
previously described [10]. Nonoxidative glucose metabolism
was calculated as glucose uptake minus glucose oxidation as
determined by indirect calorimetry.
RNA Isolation, Target Preparation, and Hybridization
RNA from skeletal muscle biopsies for studies A and B were
extracted by the guadinium thiocyanate method [11]. For
study A, targets from human skeletal muscle biopsies [12]
were hybridized to the Affymetrix HG-U133A GeneChip
(http://www.affymetrix.com), whereas for study B, targets were
hybridized to the Affymetrix Hu6800 GeneChip. For both
studies, we considered scans only for which there were more
than 10% present-calls and the GAPDH 39/GAPDH 59
expression ratio was below 3.
Real-Time PCR
Extraction of total RNA from the muscle biopsies was
performed with the TRI reagent (Sigma-Aldrich, http://www.
sigmaaldrich.com). In addition, RNA from cultured adipo-
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www1.qiagen.com). cDNA was synthesized using Superscript
II RNase H-Reverse Transcriptase (muscle biopsies; Life
Technologies, http://www.invitrogen.com) or RevertAid H-
M-MuLV Reverse Transcriptase (cultured adipocytes; Fer-
mentas, http://www.fermentas.com) and random hexamer
primers (Life Technologies). Real-time PCR was performed
in 10 ll using the ABI PRISM 7900 Sequence Detection
system (Applied Biosystems, http://www.appliedbiosystems.
com) according to the manufacturer’s instructions. Primers
and probes for TXNIP, G0S2, and BCL6 mRNA were ordered
as a ready-to-use mix of primers and FAM labeled probes
(Applied Biosystems). Peptidylprolyl isomerase A (cyclophilin A)
(PPIA) was used as an endogenous control to standardize the
amount of cDNA added to the reactions using a ready to use
mix of primers and a VIC-labeled probe (Applied Biosys-
tems). Analysis of the expression of cyclophilin A on the
microarrays from studies A and B suggested that its
expression is not signiﬁcantly altered by insulin (unpublished
data). All samples were run in duplicate, and data were
calculated using the standard curve method and expressed as
a ratio to the cyclophilin A reference. Quantiﬁcations of
TXNIP, BCL6, and G0S2 mRNA levels in study C were
performed in 96 participants (study C, Table S1).
Human Adipocyte Cell Culture
Preadipocytes of human origin were obtained and passaged
as previously described [13]. Fully differentiated cells were
treated with media (2% human serum albumin added)
supplemented with 1, 5, or 25 mM glucose with and without
1 nM insulin (a physiological concentration). After 4 h the
cells were harvested for RNA extraction.
Glucose Uptake Assays in Mouse Adipocytes and Primary
Human Skeletal Muscle Cells
Cell culture. Primary human satellite cells were isolated
from muscle biopsies obtained from healthy human volun-
teers by trypsin digestion and were grown to conﬂuent
myoblasts and differentiated into myotubes as previously
described in detail [14]. 3T3-L1 mouse ﬁbroblasts (ATCC)
were cultured in DMEM and differentiated by standard
means [15], via media supplemented with 5 lg/ml insulin, 0.25
lM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX). Uptake assays were typically performed by day 10–12
postdifferentiation for adipocytes and day 5 postdifferentia-
tion for human myotubes.
RNA interference. Human skeletal muscle cells were seeded
in six well plates at 2–3 3 10
4 cells/cm
2. At 70%–80%
conﬂuence, myoblasts were induced to differentiate. On day 2
of differentiation, cells were transfected as described pre-
viously [16] with short interfering RNA (siRNA) directed
against TXNIP (Dharmacon, http://www.dharmacon.com).
Adipocytes were differentiated in 12-well plates, and cells
were transfected with mouse Txnip-speciﬁc siRNA species
(individual siRNA sequences, Ambion, http://www.ambion.
com). We transfected 20 ng of siRNA or negative control
scrambled siRNA (Ambion) in adipocytes on day 10 post-
differentiation using Express-si delivery reagent (Genospec-
tra, http://www.panomics.com). Glucose uptake and Western
analysis followed at 48–72 h posttransfection in the presence
of high-glucose (25 mM) DMEM media.
Viral transduction. Human TXNIP was subcloned into the
pCDH1-MCS1-EF1-Puro vector (System Biosciences, http://
www.systembio.com). TXNIP or an empty vector was trans-
fected into 293TN cells (ATCC) with Fugene 6 (Roche, http://
www.roche.com) to generate pseudoviral particles. GFP was
cotransfected with a 1:100 ratio (pSIH1-H1-copGFP, System
Biosciences), and multiplicity of infection (MOI) was deter-
mined by the number of GFP-positive cells detected by
ﬂuorescence microscopy at 96 h. Cells were cultured in low
glucose (5.6 mM), transduced with an MOI of 1–2, and allowed
to express viral proteins for 96 h before initiation of glucose
uptake studies. Western blot analysis was performed on total
cellular lysates separated on SDS-PAGE and transferred to
PVDF membranes. Monoclonal antibodies were raised against
full-length TXNIP as described previously [17], and anti-
bodies to beta-actin were purchased from Sigma.
Glucose uptake assays. Virally infected or siRNA gene-
silenced adipocytes were serum starved for 4 h, then
incubated in Krebs-Ringer-Hepes with or without 100 nM
recombinant insulin for 15 min at 37 8C. We added 0.5 mCi/
ml of 2-deoxy-D-[
3H]-glucose and 0.1 mM cold 2-deoxy- D-
glucose, and the cells were incubated for ﬁve minutes at 25 8C.
Uptake was terminated with ice-cold PBS containing 25 mM
glucose, and cells were lysed in 0.5 ml of 1% Triton X-100/
0.05% SDS at 60 8C for 10 min. Lysate radioactivity was
measured by scintillation counting, and the data were
expressed in pmol/mg lysate protein-min. Nonspeciﬁc glucose
uptake was determined by the addition of cytochalasin B to
10 lM and was subtracted from measured values. Skeletal
muscle glucose uptake assays were performed essentially as
above, but with 6 nM insulin stimulation, as previously
described [14].
Resequencing of TXNIP
We resequenced the TXNIP gene along with 2,200 bp
upstream of the 59 end and 1,000 bp downstream of the 39
end in 48 individuals, 23 of whom showed expression of
TXNIP in muscle in the highest quartile, while 25 had TXNIP
expression in lowest quartile from our previous studies [9,18].
Genomic DNA was isolated from peripheral blood using
standard procedures. We used speciﬁc primers (Applied
Biosystems) to amplify the region by PCR. Sequencing was
performed using Big Dye version 3.1 Cycle Sequencing kit
(Applied Biosystems) according to the manufacturer’s in-
structions, and separation was done on the ABI3730 DNA
Analyzer. Each base was called using the PHRED software
package [19,20], and quality scores were assigned. Sequence
assembly and analysis were done using the Staden software
package [21]. Three novel single nucleotide polymorphisms
(SNPs), one novel insertion, and one novel deletion were
identiﬁed by resequencing TXNIP (Table S2).
Genetic Association Studies
We determined the pattern of genetic variation in
individuals of European origin around the TXNIP locus
(including 20 kb upstream and 10 kb downstream) using the
HAPMAP database (http://www.hapmap.org) and by genotyp-
ing an additional 33 SNPs (which also include three novel
SNPs identiﬁed by resequencing) in the HAPMAP panel (90
normal individuals of European descent). In total, the pattern
of linkage disequilibrium around TXNIP was ascertained
from 15 polymorphic SNPs (32 SNPs were monomorphic, and
six SNP assays failed). The gene lies in a region of high linkage
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(,10% minor allele frequency). We selected nine tag SNPs to
capture all genotypes and haplotypes with r
2 over 0.8 [22]. To
study the association between TXNIP variants and T2DM,
nine tag SNPs and two missense SNPs were genotyped in
;4,450 individuals. The sample population consisted of 333
Scandinavian parent–offspring trios, 1,189 discordant Scan-
dinavian sib-pairs, and 1,084 case-control pairs (969 from
Scandinavia and 125 from Canada). All case-control pairs
were individually matched for sex, age, region of origin, and
body mass index (BMI) as previously described [23]. Genotyp-
ing was performed by primer extension of multiplex products
with detection by MALDI-TOF mass spectroscopy using a
Sequenom platform. This study has .99% power to reject the
null hypothesis of no association at p , 0.05 for a 10% allele
assuming an OR of 1.3 and prevalence of diabetes of 8% [24].
Association of each tag SNP to type 2 diabetes was tested for
each subsample, and the results were combined by Mantel-
Haenszel meta-analysis. The two missense SNPs (rs6674773
and rs11537986) were monomorphic in the diabetes sample.
For a subset of nondiabetic individuals in this study, fasting
glucose and fasting insulin measurements were available. We
tested for correlation of TXNIP SNP genotypes with four
related quantitative phenotypes: fasting glucose, fasting
insulin, homeostasis model assessment (HOMA-IR) as a
measure of insulin resistance, and HOMA-b (b-cell function)
as a measure of insulin secretion. For each SNP, we tested
association to each quantitative trait under a general model, a
dominant model, and a recessive model.
Statistical Analysis
Analysis of microarray data. All scans were subjected to
global scaling to take into account intensity-related biases.
For each scan, we scaled the expression intensity of all genes
such that mean intensity of each scan equals mean intensity
of one high-quality scan (scan GSM172123 AI for study A;
scan GSM172162 for study B). We included only those probe
sets for which percentage present calls were greater than 50%
of all scans to remove probe sets that were not reliably
detected [25]. For study A, we therefore considered a total of
5,059 out of 22,283 probe sets on HG-U133A chip. For study
B, a total 1,177 out of 7,129 probe sets passed this ﬁltering
criterion.
We applied the signiﬁcance analysis of microarrays [26]
method for paired data by comparing pre- versus post-clamp
log (base 2) transformed data (with .1.5-fold change, delta ¼
0.37, and median false discovery rate ¼ 0%) to identify
insulin-regulated genes from study A. Based on this analysis,
we identiﬁed two insulin-induced genes, G0S2 (2.65-fold, p ¼
0.04), and HES1 (2.26-fold, p ¼ 0.04), and three insulin-
suppressed genes, TXNIP (2.39-fold, p¼0.04), BCL6 (2.13-fold,
p ¼ 0.04), and SLC19A2 (1.76-fold, p ¼ 0.04) from study A,
where p-values refer to Wilcoxon signed rank tests. Of these
ﬁve genes, three (G0S2, TXNIP, and BCL6) proved to replicate
in study B again using the Wilcoxon signed rank test (Table 1).
Analysis of published microarray data. We analyzed the
expression of individual genes using previously published
microarray data [18,27–29]. Normalized data from these
studies [27–29] were downloaded from the Web site for the
Diabetes Genome Anatomy Project (DGAP, http://www.
diabetesgenome.org). For interclass, unpaired comparisons,
we used the Mann-Whitney U-test, a nonparametric statistic,
to identify differences in expression of individual genes.
Spearman rank correlations were used to relate expression
levels with metabolic variables.
Analysis of TXNIP, BCL6, and G0S2 mRNA levels by real-
time PCR. The nonparametric statistic (Wilcoxon signed rank
test) was used to identify signiﬁcant differences between the
groups for TXNIP, BCL6, and G0S2 mRNA levels from study C
(Figure 1).
Generalized estimating equation analysis. Study C included
monozygotic and dizygotic twins. To relate expression data
with insulin-stimulated glucose uptake, a GEE model was used
to adjust for the interdependence between twins [9,30]. In this
model the correlation is assumed to be different for
monozygotic and dizygotic twins. The variables included in
the model were selected using a backward selection regres-
sion with a signiﬁcance level set to 0.05.
Analysis for cellular glucose uptake studies. Differences
between groups were determined using either the paired
Student t-test (adipocytes) or two-way ANOVA (myocytes).
Data are presented as mean 6 standard error.
Results
Insulin Regulates the Expression of TXNIP, G0S2, and BCL6
in Human Skeletal Muscle
We began with a systematic screen to identify genes whose
expression is responsive to the action of insulin in human
skeletal muscle. Speciﬁcally, we obtained serial muscle
Table 1. Expression of Three Insulin-Regulated Genes in Human Skeletal Muscle
Study Gene Symbol Probeset ID Preclamp (n ¼ 6) Postclamp (n ¼ 6) p-Value
Study A G0S2 213524_s_at 445.50 6 271.49 1,180.53 6 251.63 *
BCL6 203140_at 227.27 6 51.44 106.70 6 50.34 *
215990_s_at 19.46 6 9.07 8.27 6 2.08 *
TXNIP 201008_s_at 157.42 6 38.91 90.98 6 35.72 *
201009_s_at 519.01 6 234.41 250.03 6 60.42 *
201010_s_at 881.45 6 515.94 368.99 6 117.46 *
Study B G0S2 M72885_rna1_s_at 784.18 6 424.81 3,156.83 6 1,156.51 *
BCL6 U00115_at 298.77 6 304.04 77.19 6 103.83 *
TXNIP S73591_at 5,031.56 6 2426.53 2,839.52 6 1,827.90 *
Values are mean 6 standard deviation. p-Values refer to Wilcoxon signed rank test. *, p , 0.05.
doi:10.1371/journal.pmed.0040158.t001
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euglycemic hyperinsulinemic clamp using two different
clinical protocols (study A and study B), each of which
examined six individuals (see Figure S1; Table S1; and
Methods). We then proﬁled gene expression in these biopsies
using oligonucleotide microarrays. After stringent correction
for multiple hypotheses testing, we identiﬁed three genes
(G0S2, TXNIP, and BCL6) (Table 1) exhibiting differential
expression before and after insulin treatment in both studies.
All three genes were then independently validated by real-
time PCR as being truly insulin responsive using archived
RNA samples from a third clamp protocol (study C) that
involved a panel of 96 young nondiabetic individuals (see
Figure S1; Table S1; and Methods). Note that the expression
of these three genes changed reproducibly across three
different clamp protocols and quantitation platforms, sug-
gesting that they represent robust changes in response to
insulin.
Of these three genes, G0S2 was strongly induced by insulin,
while TXNIP and BCL6 were consistently repressed by insulin
(Figure 1). To our knowledge, none of these genes has
previously been associated with insulin signaling. G0S2 was
recently shown to be a target gene of PPARa [31], while BCL6
is a proto-oncogene that suppresses p53 and is implicated in
the pathogenesis of human B cell lymphoma [32]. BCL6 has
also been reported to interact with PPARd [33]. TXNIP was
originally identiﬁed in a yeast two-hybrid screen for proteins
that bind to thioredoxin, a protein that undergoes NADPH-
dependent reduction and has roles in cellular signaling and
reactive oxygen species (ROS) metabolism [34]. It is notable
that whereas we identify TXNIP expression as being strongly
repressed by insulin in vivo (Figure 1), many previous studies
have identiﬁed TXNIP as being sharply induced by glucose in
a variety of cell types, including pancreatic islets [35],
ﬁbroblasts [36], mesangial kidney cells [37], rat cardiomyo-
cytes, and vascular endothelial and smooth muscle cells [38].
TXNIP Expression Is Elevated in Skeletal Muscle of
Individuals with Impaired Glucose Tolerance or T2DM
Having identiﬁed three insulin-regulated genes, we sought
to determine whether any of them exhibit altered expression
in diabetes in humans. We analyzed two previously published
microarray datasets of human diabetic and control muscle
[18,27] and found that TXNIP expression was elevated in
northern Europeans with impaired glucose tolerance (IGT) or
T2DM (Figure 2A). While TXNIP expression was also elevated
in the muscle of Mexican Americans with T2DM (Figure 2B),
we found no evidence of an elevation of TXNIP expression in
the muscle of healthy Mexican Americans with a family
history of T2DM (Figure 2B). Although elevated circulating
glucose levels could account for the observed differences in
IGT and T2DM, it is notable that in our previous study [18],
presented in Figure 2A, the muscle biopsies were obtained
during conditions in which plasma glucose was clamped at
the same level in all individuals.
Suppression of TXNIP Expression by Insulin Requires
Insulin Receptor Signaling
To determine whether the suppression of TXNIP by insulin
in vivo is simply secondary to a decrease in circulating
glucose, or due to a direct effect of insulin signaling, we
examined Txnip gene expression using published microarray
data from mice with disrupted insulin receptor signaling
[28,29]. Txnip gene expression was more highly expressed (1.5-
fold, p , 0.05) in the muscle of mice treated with
streptozotocin, an agent that is selectively toxic to pancreatic
b-cells and results in insulin deﬁciency and hyperglycemia.
Txnip expression levels reverted (0.53-fold, p , 0.05) to
Figure 1. Effects of Insulin on TXNIP, BCL6, and G0S2 Expression in
Human Muscle In Vivo
mRNA levels were measured in skeletal muscle biopsies of healthy
individuals before and after the hyperinsulinemic euglycemic clamp for
(A) TXNIP (n¼96, p , 1310
 14), (B) BCL6 (n¼90, p , 1310
 5), and (C)
G0S2 (n¼95, p , 1 310
 16). Levels were measured using real-time PCR
and normalized to cyclophilin A mRNA. Inset shows the distribution of
expression changes over individuals. p-Values refer to the Wilcoxon
signed rank statistic.
doi:10.1371/journal.pmed.0040158.g001
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insulin, which normalizes circulating glucose levels. However,
in the muscle insulin receptor knockout mouse [29], treat-
ment of streptozotocin-treated mice with insulin failed to
suppress Txnip expression (1.33-fold increase with insulin, p¼
0.08), despite the fact that glucose was well controlled in these
mice. These data indicate that the suppression of Txnip by
insulin is not simply secondary to a reduction in circulating
glucose concentrations, but rather or in addition, requires
intact insulin receptor signaling.
TXNIP Expression Is Elevated by Glucose and Suppressed
by Insulin in Human Muscle and Fat Cells in Culture
To further conﬁrm insulin’s effect on TXNIP gene
regulation, we analyzed TXNIP expression in cell culture.
First, we analyzed microarray data from a published study
that proﬁled human primary cultured myotubes following
insulin treatment [39]. TXNIP expression was suppressed by
more than 1.5-fold (p , 0.003) after four hours of insulin
treatment, clearly demonstrating that the suppression of
TXNIP can occur in the absence of any changes in circulating
glucose concentrations. We also performed in vitro assays of
TXNIP expression in a human adipocyte cell line (Methods)
that is known to respond to insulin by stimulating glucose
uptake. TXNIP expression increased following elevations in
glucose concentration, and was suppressed by insulin (Figure
3). Together, these cell culture studies conﬁrm that TXNIP
expression is reciprocally regulated by insulin and glucose in
human muscle and fat tissues.
The Promoter of TXNIP Contains Conserved Regulatory
Elements That May Account for Its Reciprocal Regulation
by Insulin and Glucose
We hypothesized that the reciprocal regulation of TXNIP
expression by insulin and glucose is likely mediated by highly
conserved regulatory elements in the vicinity of its promoter
(Figure S2). First, it contains tandem E-boxes that have been
shown to account for the brisk response of TXNIP to glucose
in the pancreas [40]. The promoter also contains an
evolutionarily conserved binding site for the forkhead family
of transcription factors. Because these forkhead family
members are known to be excluded from the nucleus via
Akt-mediated phosphorylation downstream of insulin signal-
ing [41], and since TXNIP induction by glucose is blunted by
the activation of the phosphatidylinositol-3-kinase/Akt path-
way [38], this class of transcription factors represent excellent
candidate mediators of the insulin-stimulated repression of
TXNIP.
TXNIP Expression Is Inversely Correlated with Insulin-
Stimulated Glucose Uptake
We found that TXNIP expression is inversely correlated
with the total body rate of insulin-stimulated glucose
Figure 3. Effects of Glucose and Insulin on the Expression of TXNIP in
Cultured Human Adipocytes
Human adipocytes were cultured in the presence (black bars) or absence
(white bars) of 1 nM insulin at varying levels of glucose. Data are
presented as mean 6 standard deviation, normalized to the untreated
control. * p , 0.05, Mann-Whitney U-test.
doi:10.1371/journal.pmed.0040158.g003
Figure 2. TXNIP Expression in Individuals with Diabetes or at Risk for
Developing Diabetes
(A) TXNIP expression levels from individuals with NGT, IGT, or T2DM,
using data from our previously published microarray study [18]. * p ,
0.02; ** p , 0.01, Mann-Whitney U-test.
(B) TXNIP expression levels from NGT individuals with family history of
T2DM (FHþ) or without (FH ), as well as individuals with T2DM, using
data from a previously published microarray study [27]. * p , 0.03,
Mann-Whitney U-test.
doi:10.1371/journal.pmed.0040158.g002
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TXNIP Regulates Glucose Uptake in Humansmetabolism in humans (Figure 4). This relationship is robust
in individuals with normal glucose tolerance (NGT) (r¼ 0.57,
p¼0.02) or IGT (r¼ 0.86, p¼0.006), but not in patients with
T2DM (r¼ 0.21, p¼0.41). To exclude the possibility that the
relationship between TXNIP expression and glucose uptake
could be a consequence, rather than a cause, of the metabolic
derangements that precede T2DM we also related the
expression of skeletal muscle TXNIP to glucose uptake in 96
healthy, young, nondiabetic individuals (Methods, study C).
Since both dizygotic and monozygotic twins were included in
the analysis, we used a generalized estimating equation model
to correct for the relationship between twin pairs (Methods).
In the analysis, we modeled insulin-stimulated glucose uptake
as a function of age, sex, basal and insulin-stimulated TXNIP
expression, zygosity, birth weight, percentage of body fat,
BMI, and VO2max. Only four of these variables had explan-
atory power. Basal (p¼0.02) and insulin-stimulated (p , 0.01)
TXNIP expression as well as BMI (p , 0.01) were inversely
correlated, while VO2max (p , 0.01) was positively correlated
with insulin-stimulated glucose uptake (Table 2). These data
are consistent with the notion that TXNIP is an independent
determinant of insulin-stimulated glucose uptake in humans.
TXNIP Expression Governs Glucose Uptake in Insulin-
Responsive Cells
To directly test if TXNIP may regulate glucose uptake, we
used genetic manipulations to alter the gene’s expression in
mouse and human cell lines. First we performed in vitro
studies on an insulin-sensitive cell line, the adipocyte differ-
entiated 3T3-L1. Incubation of the adipocytes with high
glucose results in a potent induction of TXNIP protein
(unpublished data). A 2-fold forced overexpression of TXNIP
using lentiviral transduction resulted in both diminished
basal and insulin-stimulated glucose uptake (59% and 28%
reduction, respectively, Figure 5A). In agreement with this
result, forced reduction of TXNIP expression by siRNA gene
silencing achieved the opposite effect and enhanced both
basal and insulin-stimulated glucose uptake (157% and 61%,
respectively, Figure 5B). In addition, we examined the effects
of TXNIP reduction in primary human skeletal muscle
myocytes by siRNA gene silencing. Again, we observed a
signiﬁcant increase in both basal and insulin-stimulated
glucose uptake (Figure 5C). Together, these in vitro studies
indicate that changes in TXNIP expression can directly
inﬂuence glucose uptake in insulin-responsive cells.
Do Genetic Variants in the TXNIP Gene Increase
Susceptibility to T2DM?
While the above studies demonstrate that TXNIP is a
physiologic regulator of peripheral glucose homeostasis in
humans, we were next interested in determining whether
genetic variation in this gene may be associated with
measures of insulin resistance or T2DM in humans. We
assessed the pattern of common genetic variation encompass-
ing the TXNIP gene using data from the HapMap project and
by resequencing the gene (Methods; Table S2). Then we
performed a genetic association study of nine ‘‘tag’’ SNPs that
capture the most common variation observed within the
vicinity of this gene (Figure 6). This study was in part
motivated by the observation that TXNIP is located on
Chromosome 1q21.1, a region that has shown perhaps the
most consistent linkage to T2DM [42,43]. In a clinical sample
of 4,450 Scandinavian individuals, no signiﬁcant association
was detected between SNPs in TXNIP and T2DM (Methods;
Table 3). Also, no signiﬁcant association was observed
between the genotypes and four quantitative phenotypes:
fasting glucose, fasting insulin, HOMA-IR as a measure of
insulin resistance, and HOMA-b as a measure of insulin
secretion (Table S3). Although we did not detect poly-
Figure 4. Insulin-Mediated Glucose Uptake Versus TXNIP Expression
This relationship is shown for individuals with NGT, IGT, and T2DM. Linear
regression parameters are indicated for each of the groups. Data are
from our previously published microarray study [18].
doi:10.1371/journal.pmed.0040158.g004
Table 2. Factors Influencing Insulin-Stimulated Glucose Uptake
in Humans
Factors Regression Coefficients p-Value
TXNIP before clamp  4.18 ¼ 0.02
TXNIP after clamp  20.29 , 0.01
BMI  0.35 , 0.01
VO2max 0.11 , 0.01
The generalized estimating equation model was used to determine whether basal and
insulin-stimulated TXNIP expression, birth weight, age, sex, zygosity, percentage of body
fat, BMI, or VO2max influence insulin-stimulated glucose uptake. The final model was
reached using backward selection regression.
doi:10.1371/journal.pmed.0040158.t002
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TXNIP Regulates Glucose Uptake in Humansmorphisms in TXNIP that are associated with T2DM, it is still
formally possible that inherited variation in other genes in
the TNXIP pathway may predispose to the risk of developing
T2DM.
Discussion
We have combined human physiology, genome-wide
expression proﬁling, genetic association testing, and cellular
studies to spotlight TXNIP as a physiologic regulator of
peripheral glucose uptake in humans. Our results build on
murine studies that have established a role for this protein in
the liver in the regulation of fasting:feeding transitions
[44,45] and in b-cell glucose toxicity [35]. While genetic
variation in TXNIP does not predispose one’s inherited risk
for developing T2DM, TXNIP nonetheless appears to play a
physiologic role in glucose homeostasis in muscle and in fat.
Key novel results from the current study include the ﬁnding
Figure 5. Genetic Manipulation of TXNIP Expression Affects Both Basal and Insulin-Stimulated Glucose Uptake in Cultured Adipocytes and in Primary
Skeletal Muscle Myocytes
(A) Differentiated 3T3-L1 adipocytes cultured in 5.6 mM glucose were transduced with human TXNIP or empty virus particles and allowed to express the
genes for 96 h. Cell lysates were immunoblotted using antibodies against TXNIP or actin. The exogenous viral human TXNIP protein is present as the
more slowly migrating of the two bands. Glucose uptake with and without insulin was measured as described in Methods. Each data point represents
an n ¼ 4. * p , 0.02; ** p , 0.005.
(B) Adipocytes cultured in 25 mM glucose were transfected with siRNA against TXNIP or with negative control siRNA and assayed 48 h posttransfection.
Immunoblotting and glucose uptake are as above. n ¼ 4 for each data point. * p , 0.02; ** p , 0.001.
(C) Human skeletal muscle myoblasts obtained from biopsy were differentiated into myotubes in culture and transfected with siRNA against TXNIP or
with negative control siRNA. Glucose uptake was measured at 72 h post-transfection with n¼4 for each data point. Each experiment was performed at
least three times. * p , 0.01
doi:10.1371/journal.pmed.0040158.g005
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insulin and by glucose, that elevations in TXNIP can inhibit
glucose uptake, and that TXNIP expression levels are
consistently elevated in humans with T2DM and prediabetes.
Our study shows that TXNIP is part of a negative feedback
mechanism that regulates glucose uptake into cells (Figure
7A). Such a mechanism may serve to prevent excess glucose
uptake or metabolism [46]. At present, it is not clear whether
TXNIP inﬂuences the metabolic fate of glucose—future
studies will be required to address this important issue.
Because TXNIP expression is suppressed by insulin signaling,
it appears that TXNIP inﬂuences both insulin-dependent and
insulin-independent arms of glucose uptake into cells. Of
note, epidemiological studies have suggested roles for both
insulin-dependent and insulin-independent pathways in the
development of T2DM [4].
Recent genomic studies have pointed to mitochondrial
dysfunction and to ROS as possible culprits in the etiology of
insulin resistance [18,27,47,48]. At present, we do not know
how mitochondrial dysfunction and ROS are related to each
other in the pathogenesis of insulin resistance. The current
study, in combination with other recent studies, suggests that
TXNIP may lie upstream of both of these processes. First,
TXNIP expression is induced by glucocorticoids [49] and by
glucose, and TXNIP elevations can stimulate ROS production
[38]. Hence TXNIP represents a candidate intermediate
linking diabetogenic stimuli to ROS production. Second, we
have observed an inverse correlation in the expression of
TXNIP and mitochondrial oxidative phosphorylation (un-
published data), and previous studies have shown that TXNIP
can serve as a transcriptional repressor [50]. Taken together,
these data raise the hypothesis that TXNIP may lie upstream
of the elevations in ROS and mitochondrial dysfunction that
accompany insulin resistance.
Importantly, our ﬁndings, in combination with recent
studies focused on the pancreatic b-cell [40], provide
molecular insights into the pathogenesis of impaired insulin
secretion and action (Figure 7B) that characterize the
prediabetic state [1,51]. Hyperglycemia has long been known
to exacerbate b-cell failure [52,53] and impaired skeletal
muscle glucose uptake [54] via a process often termed glucose
toxicity. At present the molecular basis for glucose toxicity is
not known, although ROS represent a candidate mediator
[46,47]. A recent study [40] reported that TXNIP is glucose
inducible in pancreatic b-cells and may mediate b-cell death
through apoptosis. Our present study has led to the novel
ﬁnding that TXNIP also plays a role in controlling peripheral
glucose uptake in humans and may be an important target
mediating effects of insulin. Together, these studies suggest
that TXNIP may be involved in glucose toxicity both in b-cells
and in the periphery, helping to reconcile the dynamic
relationship between insulin deﬁciency and impaired glucose
uptake that is observed in the prediabetic state (Figure 7B).
Interventions aimed at modulating TXNIP activity may
therefore help curtail this vicious cycle that eventually leads
to overt T2DM.
Figure 6. Pattern of Genetic Variation at the TXNIP Locus
Linkage disequilibrium between SNPs was analyzed using Haploview
[55], and D9 values were calculated with 95% confidence intervals. D9
plot for each square depicts the magnitude of linkage disequilibrium for
a pair of markers, red indicates high D9 with high logarithm of odds
(LOD) score, while white indicates low D9 with low LOD score, and blue
indicates high D9 with low LOD score.
doi:10.1371/journal.pmed.0040158.g006
Table 3. Association of TXNIP Tag SNPs with T2DM
SNP Alleles Minor Allele Frequency Odds Ratio 95% Confidence Interval p-Value
rs1535921 G/A 0.36 0.99 0.89–1.11 0.453
rs4970862 C/T 0.40 1.03 0.93–1.14 0.698
rs4126494 A/G 0.04 0.99 0.79–1.24 0.448
rs2236566 G/T 0.07 1.02 0.83–1.25 0.568
rs16827243 G/A 0.06 0.94 0.75–1.18 0.302
rs17221756 A/G 0.01 1.36 0.88–2.09 0.166
rs9245 C/A 0.07 0.88 0.71–1.08 0.107
rs4636400 T/G 0.42 1.02 0.92–1.12 0.617
rs704985 G/C 0.47 0.98 0.87–1.09 0.358
TXNIP tag SNPs over 2% frequency were examined for association with T2DM; the different subsamples in our study were combined by Mantel-Haenszel meta-analysis. p-Values refer to
two-tailed t-test.
doi:10.1371/journal.pmed.0040158.t003
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Found at doi:10.1371/journal.pmed.0040158.sg001 (352 KB PDF).
Figure S2. The Promoter of TXNIP Contains a Conserved Binding
Site for the Tandem E-Boxes and for the Forkhead Family of
Transcription Factors in Four Species (Human, Mouse, Rat, and Dog)
Positions are relative to translation start site of TXNIP gene. See [56]
for tandem E-boxes and [35] for forkhead family of transcription
factors.
Found at doi:10.1371/journal.pmed.0040158.sg002 (298 KB PDF).
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Found at doi:10.1371/journal.pmed.0040158.st001 (58 KB PDF).
Table S2. TXNIP Resequencing in 48 Individuals
Found at doi:10.1371/journal.pmed.0040158.st002 (35 KB PDF).
Table S3. Genotype-Phenotype Correlations of TXNIP Tag SNPs with
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TXNIP Regulates Glucose Uptake in HumansEditors’ Summary
Background. An epidemic of diabetes mellitus is threatening world
health. 246 million people (6% of the world’s population) already have
diabetes and it is estimated that within 20 years, 380 million people will
have this chronic disease, most of them in developing countries.
Diabetes is characterized by high blood sugar (glucose) levels. It arises
when the pancreas does not make enough insulin (type 1 diabetes) or
when the body responds poorly to insulin (type 2 diabetes). Insulin,
which is released in response to high blood glucose levels, instructs
muscle, fat, and liver cells to take glucose (a product of food digestion)
out of the bloodstream; cells use glucose as a fuel. Type 2 diabetes,
which accounts for 90% of all cases of diabetes, is characterized by
impaired glucose uptake by target tissues in response to insulin (this
‘‘insulin resistance’’ is one of the first signs of type 2 diabetes) and
inappropriate glucose release from liver cells. Over time, the pancreas
may also make less insulin. These changes result in poor glucose
homeostasis (inadequate control of blood sugar levels), which can cause
life-threatening complications such as kidney failure and heart attacks.
Why Was This Study Done? If the world diabetes epidemic is to be
halted, researchers need a better understanding of glucose homeostasis
and need to identify which parts of this complex control system go awry
in type 2 diabetes. This information might suggest ways to prevent type
2 diabetes developing in the first place and might reveal targets for
drugs that could slow or reverse the disease process. In this study, the
researchers have used multiple approaches to identify a new mediator of
glucose homeostasis and to investigate whether this mediator is causally
involved in the development of type 2 diabetes.
What Did the Researchers Do and Find? The researchers took small
muscle samples from people who did not have diabetes before and after
increasing their blood insulin levels and used a technique called
‘‘microarray expression profiling’’ to identify genes whose expression
was induced or suppressed by insulin. One of the latter genes was
thioredoxin interacting protein (TXNIP), a gene whose expression is
strongly induced by glucose yet suppressed by insulin. They next used
previously published microarray expression data to show that TXNIP
expression was consistently higher in the muscles of patients with
diabetes or prediabetes (a condition in which blood glucose levels are
slightly raised) than in normal individuals. The researchers then
examined whether TXNIP expression was correlated with glucose uptake,
again using previously published data. In people with no diabetes and
those with prediabetes, as glucose uptake rates increased, TXNIP
expression decreased but this inverse correlation was missing in people
with diabetes. Finally, by manipulating TXNIP expression levels in insulin-
responsive cells grown in the laboratory, the researchers found that
TXNIP overexpression reduced basal and insulin-stimulated glucose
uptake but that reduced TXNIP expression had the opposite effect.
What Do These Findings Mean? These results provide strong evidence
that TXNIP is a regulator of glucose homeostasis in people. Specifically,
the researchers propose that TXNIP regulates glucose uptake in the
periphery of the human body by acting as a glucose- and insulin-
sensitive switch. They also suggest how it might be involved in the
development of type 2 diabetes. Early in the disease process, a small
insulin deficiency or slightly raised blood sugar levels would increase
TXNIP expression in muscles and suppress glucose uptake by these cells.
Initially, the pancreas would compensate for this by producing more
insulin, but this compensation would eventually fail, allowing blood
sugar levels to rise sufficiently to increase TXNIP expression in the
pancreas. Previously published results suggest that this would induce
the loss of insulin-producing cells in the pancreas, thus further reducing
insulin production and glucose uptake in the periphery and, ultimately,
resulting in type 2 diabetes. Although there are many unanswered
questions about the exact role of TXNIP in glucose homeostasis, these
results help to explain many of the changes in glucose control that occur
early in the development of diabetes. Furthermore, they suggest that
interventions designed to modulate the activity of TXNIP might break the
vicious cycle that eventually leads to type 2 diabetes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040158.
  The MedlinePlus encyclopedia has pages on diabetes
  The US National Institute of Diabetes and Digestive and Kidney
Diseases has information for patients on diabetes
  Information on diabetes is available for patients and professionals
from the US Centers for Disease Control and Prevention
  The American Diabetes Association provides information on diabetes
for patients
  International Diabetes Federation has information on diabetes and a
recent press release on the global diabetes epidemic
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TXNIP Regulates Glucose Uptake in Humans